BioCentury
ARTICLE | Clinical News

FDA approves Teva's QVAR RediHaler new formulation

September 29, 2017 9:26 PM UTC

FDA approved QVAR RediHaler beclomethasone dipropionate from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) for maintenance treatment of asthma as a prophylactic therapy in patients 4 years and older. Teva said it expects to launch the product in 1Q18 in both 40 µg and 80 µg doses. The breath-actuated metered-dose inhaler (MDI) has the same active ingredient as Teva's currently approved QVAR formulation, but with a different mode of delivery that does not require priming before use. The company said it will discontinue the current QVAR MDI upon the launch of QVAR RediHaler...